Abstract
This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
CNS & Neurological Disorders - Drug Targets
Title:Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study
Volume: 11 Issue: 2
Author(s): Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri
Affiliation:
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
Abstract: This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Export Options
About this article
Cite this article as:
Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri , Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269669
DOI https://dx.doi.org/10.2174/187152712800269669 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angelica Injection Reduces Cognitive Impairment during Chronic Cerebral Hypoperfusion through Brain-Derived Neurotrophic Factor and Nerve Growth Factor
Current Neurovascular Research Editorial (Hot Topic: Artificial Intelligence Techniques in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Nano Prussian Yellow Film Modified Electrode: A Cathode Material for Aqueous Potassium Ion Secondary Battery with Zinc Anode
Current Nanoscience Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research Differences in Functional Brain Activation and Hippocampal Volume Among Amnestic Mild Cognitive Impairment Subtypes
Current Alzheimer Research The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Leveraging on Active Site Similarities; Identification of Potential Inhibitors of Zinc-Finger and UFSP domain Protein (ZUFSP)
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Efficacy of Celecoxib Adjunct Treatment on Bipolar Disorder: Systematic Review and Meta-Analysis
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Preface [Hot topic: Mitochondria as a Target of Medicinal Chemistry (Guest Editor: Dongchon Kang)]
Current Medicinal Chemistry Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Current Medicinal Chemistry Immunologic Effects of Psychotropic Pharmaco-Therapeutics
Current Psychopharmacology p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Parkinson’s Disease: A Review from Pathophysiology to Treatment
Mini-Reviews in Medicinal Chemistry Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Editorial [ Production and Fate of Amyloid Peptides: Recent Advances and Perspectives ]
Current Alzheimer Research Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews